Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency
Authors:
Open Access
- 18 August 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1614223
Abstract
Background: Immune checkpoint inhibitors (ICIs) are effective against solid tumors but can trigger immune-related adverse events (irAEs), including adrenal insufficiency (AI). Given its impact on treatment efficacy and patient quality of life, understanding the clinical characteristics and outcomes of ICI-induced AI (ICI-AI) is critical.Methods: We conducted a retrospective analysis of 46 patients diagnosed with ICI-AI at a single center (May 2019–July 2024) and reviewed clinical trials/real-world studies on ICI-AI.Results: The cohort included 22 cases of isolated adrenocorticotropic hormone deficiency (IAD), 23 of hypophysitis, and 1 of primary adrenal insufficiency (PAI). Median time to AI onset was 7.8 months (range: 1.5–27.4), with a median of 7 ICIs cycles (range: 1–21). Common symptoms were fatigue, anorexia, and nausea; comorbidities included hypothyroidism (41.3%) and hyponatremia (63%). No ACTH-deficient patients recovered during follow-up, but glucocorticoid replacement alleviated symptoms in most cases (45/46). The objective remission rate for underlying malignancies post-AI was 63%. Concurrent irAEs in other organs were rare (3 cases).Conclusion: The median time to AI onset and ICIs cycles administered are key indicators of AI development. Both IAD and hypophysitis are common secondary AI manifestations; glucocorticoid replacement enables safe ICIs continuation.Keywords
This publication has 54 references indexed in Scilit:
- Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysisJournal of Cancer Research and Clinical Oncology, 2023
- Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsThe Oncologist, 2021
- Optimized PD-L1 scoring of gastric cancerGastric Cancer, 2021
- Cardiotoxicity of Immune Checkpoint InhibitorsCurrent Oncology Reports, 2021
- Isolated ACTH deficiency induced by cancer immunotherapy: a systematic reviewPituitary, 2021
- Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisisEndocrine, 2021
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical PearlsCurrent Oncology Reports, 2020
- Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanomaCancer Medicine, 2019
- Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndromePituitary, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018